ArticleJournal of thoracic disease2026
Optimal drug regimens for squamous non-small cell lung cancer: a systematic review and a Bayesian network meta-analysis of randomized trials.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current treatment options for patients with squamous non-small cell lung cancer (sqNSCLC) include immune checkpoint inhibitors combined with chemotherapy, monotherapy with immune therapy, and platinum-based doublet chemotherapy, among others. However, there is still a lack of systematic comparisons regarding the relative efficacy and safety of these regimens. This study aims to comprehensively assess the clinical benefits [such as overall survival (OS), progression-free survival (PFS)] and adverse event rates across different treatment strategies via a network meta-analysis, providing evidence-based guidance for individualized treatment decisions in sqNSCLC patients. Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science from inception to May 3, 2025 for eligible randomized controlled trials (RCTs). The primary outcome measures were PFS and OS; secondary outcomes included objective response rate (ORR) and grade ≥3 treatment-related adverse events (≥3 TRAEs). A network meta-analysis was carried out using Stata 16.0 and R 4.4.0. Results: A total of 32 RCTs, involving 9,652 participants, were included. This study analyzed 18 different treatment strategies. The network meta-analysis showed that for PFS, paclitaxel-based doublet chemotherapy combined with programmed cell death-1 and programmed death-ligand 1 [PD-(L)1] checkpoint inhibitors [surface under the cumulative ranking curve (SUCRA): 96.52%] and gemcitabine-based doublet chemotherapy combined with PD-(L)1 checkpoint inhibitors (SUCRA: 85.16%) were the most effective. For OS, paclitaxel-based doublet chemotherapy combined with a Toll-like receptor-2 agonist (CADI-05) (SUCRA: 92.11%), paclitaxel-based doublet chemotherapy combined with PD-(L)1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibitors (SUCRA: 89.65%), and paclitaxel-based doublet chemotherapy combined with PD-(L)1 checkpoint inhibitors (SUCRA: 83.58%) were the top three choices. The combination of paclitaxel-based doublet chemotherapy with PD-(L)1 checkpoint inhibitors (SUCRA: 87.00%) was associated with the best improvement in ORR. Conclusions: For first-line treatment of sqNSCLC, the current evidence supports the use of paclitaxel-based doublet chemotherapy combined with PD-(L)1 checkpoint inhibitors as one of the preferred treatment options. However, more high-quality trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.